Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 24, 2025Expert Review of Hematology

Mesenchymal stromal cells for the prophylaxis of graft-versus-host disease after hematopoietic stem cell transplantation: a meta-analysis of randomized controlled trials

View Full Paper
Ask AI
Bookmark
Share

Authors

SRSushmitha RameshbabuHKHariniska Jayaraman KannanMMMudit Moondra

Discussion

Loading...

Member takes

Overview

Meta-analysis reveals that mesenchymal stromal cells improve overall survival and reduce graft-versus-host disease in hematopoietic stem cell transplant patients, suggesting a potential effective strategy.

Key Points

  • MSC prophylaxis significantly improves overall survival with a relative risk of 1.12 in HSCT patients.
  • There is a notable reduction in the incidence of acute GVHD and chronic GVHD with relative risks of 0.67 and 0.65, respectively.
  • The analysis included eight randomized controlled trials with a total of 570 patients, ensuring robust data for the findings.
  • No significant increase in relapse rates, infections, or adverse events was observed, indicating safety in MSC use for GVHD management.

Cite This Study

Rameshbabu et al. (2025) studied this question.

synapsesocial.com/papers/689a0621e6551bb0af8cded5https://doi.org/10.1080/17474086.2025.2535422
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Mesenchymal stromal cells in the prophylaxis of graft vs host disease: A meta analysis2025
  2. 2An optimized MSC product promotes GvHD prophylaxis through exosome-mediated regulatory T cell induction2025 · 1 citations
  3. 3Immunological mechanisms underlying the novel application of mesenchymal stromal cell-derived extracellular vesicles (MSC-EVs) in graft-versus-host disease (GvHD) therapy2025 · 3 citations
  4. 4Mesenchymal stem cells for treating gastrointestinal-involved steroid-refractory acute graft-versus-host disease: A multicenter, single-arm, pivotal clinical Trial2025
  5. 5Mesenchymal stem cells for the adjunctive treatment of cytomegalovirus pneumonia in hematopoietic stem cell transplant recipients: a Single-center prospective study2025 · 1 citations